Clinical Trials Directory

Trials / Completed

CompletedNCT00068263

3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection

A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
Sponsor
Radiation Therapy Oncology Group · Network
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: 3-dimensional conformal radiation therapy delivers a high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of 3-dimensional conformal radiation therapy in treating women who have undergone lumpectomy and axillary node dissection for stage I or stage II breast cancer.

Detailed description

OBJECTIVES: * Determine the technical feasibility and reproducibility of three-dimensional conformal radiotherapy confined to the region of the lumpectomy cavity in women with stage I or II breast cancer. * Determine the cosmetic results in patients treated with this regimen. * Determine the complication rates in patients treated with this regimen. * Determine the local control rate in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients undergo three-dimensional conformal radiotherapy twice daily for 5 days beginning within 8 weeks after surgery. Patients are followed at 6 weeks, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 19-46 patients will be accrued for this study within 6.3 to 15.3 months.

Conditions

Interventions

TypeNameDescription
RADIATIONradiation therapy

Timeline

Start date
2003-08-01
Primary completion
2005-06-01
Completion
2016-12-01
First posted
2003-09-11
Last updated
2017-01-04

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00068263. Inclusion in this directory is not an endorsement.